In a significant move within the healthcare industry, Dr. Reddy’s Laboratories Ltd. has announced the acquisition of the MenoLabs business, a prominent player in women’s health and dietary supplements, from Amyris, Inc. This acquisition occurred during Amyris’ Chapter 11 sales process. At the forefront of this deal is the entire portfolio of MenoLabs supplements, which […]
Dr. Reddy’s Laboratories said that it has signed a licensing deal with New Jersey-based Slayback Pharma for acquiring rights in the latter’s Brimonidine Tartrate Ophthalmic Solution 0.025%. Brimonidine Tartrate Ophthalmic Solution 0.025% is the private label equivalent of Lumify in the US. Lumify, which is an over-the-counter (OTC) eyedrop, can be used for easing the […]
Dr. Reddy’s Laboratories said that it has launched Dr. Reddy’s Sorafenib Tablets, USP, 200 mg in the US market following the approval of the US Food and Drug Administration (FDA). Dr. Reddy’s Sorafenib Tablets, USP, 200 mg is a generic of Bayer HealthCare Pharmaceuticals’ cancer drug Nexavar (sorafenib). The product will be available in 200 […]
Dr. Reddy’s Laboratories and its partner Senores Pharmaceuticals have launched Ketorolac Tromethamine Tablets USP, 10 mg, in the US market. The launched product is a generic equivalent of Toradol Tablets, 10 mg, which has the approval of the US Food and Drug Administration (FDA) for the short-term treatment of moderate to severe pain in adults. […]
Dr. Reddy’s Laboratories said that it has relaunched over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Bayer HealthCare’s Aleve, in the US market. The relaunch is as per the approval from the US Food and Drug Administration (FDA), said the Indian pharma company. According to Dr. Reddy’s Laboratories, its OTC Naproxen […]
Dr. Reddy’s Laboratories has launched Ertapenem for Injection, 1 g/vial, a generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial, which has approval from the US Food and Drug Administration (FDA) for the treatment of various bacterial infections. The Indian pharma company has extended its partnership with Gland Pharma to launch Ertapenem for […]
Dr. Reddy’s Laboratories has launched Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a generic of BioMarin’s Kuvan (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, approved by the US Food and Drug Administration (USFDA) for the treatment of phenylketonuria. Sapropterin dihydrochloride is indicated for the treatment of variant types of phenylketonuria (hyperphenylalaninaemia) associated with deficiency […]
Indian pharma company Dr. Reddy’s Laboratories has launched a generic version of phenylalanine hydroxylase activator Sapropterin Dihydrochloride Tablets, for oral use, in the US market. Sapropterin Dihydrochloride Tablets are indicated in the US for reducing blood phenylalanine (Phe) levels in adult and pediatric patients, aged one month and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- […]
Dr. Reddy’s Laboratories has announced the appointment of Marc Kikuchi as the CEO of its North America Generics unit. Kikuchi, who brings over 20 years of industry experience, will assume his new role at the company’s Princeton office in the United States. His leadership will oversee Dr. Reddy’s North American Generics business as the company […]